Ocular Therapeutix to present at Clinical Trials at the Summit 2025

The CTS 2025 meeting will take place on June 21, 2025 in Las Vegas, Nevada.
(Image credit: AdobeStock/somchaij)

Clinical Trials at the Summit will take place on June 21, 2025 in Las Vegas, Nevada. This invite-only event is now in its fifth year, and will bring together ophthalmologists, industry partners, and thought leaders to discuss the current areas of patient need and the clinical trials that are underway to meet those needs.

Among the industry partners who will be in attendance at the event is Ocular Therapeutix, Inc. At the meeting, the company will participate in several discussions and presentations as they share their ongoing work in developing tyrosine kinase inhibitor (TKI) candidates for the treatment of several retinal diseases, including wet age-related macular degeneration (AMD) and diabetic retinopathy (DR).

The following is a list of presentations Ocular Therapeutix will participate in at Clinical Trials at the Summit (CTS) 2025.

• Company Presentation: Ocular Therapeutix
  Friday, June 20, 2025, 7:55 – 8:05 PM PT
  Presenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
• Sustained-Release Axitinib Hydrogel (OTX-TKI) for Wet AMD: US Phase 1 Study Results
  Saturday, June 21, 2025, 9:05 – 9:09 AM PT
  Presenter: Patricio G. Schlottmann, MD
• SOL-1 and SOL-R: Pivotal Phase 3 Trials Evaluating OTX-TKI for Wet AMD
  Saturday, June 21, 2025, 9:09 – 9:13 AM PT
  Presenter: Andrea Gibson, PhD, Senior Vice President, Medical Collaborations
• Safety and Efficacy of OTX-TKI for Diabetic Retinopathy: HELIOS Phase 1 Study
  Saturday, June 21, 2025, 9:25 – 9:29 AM PT
  Presenter: Dilsher S. Dhoot, MD
• Panel: SOL Program Unpacked: Exploring OTX-TKI’s Potential with Trial Experts
  Saturday, June 21, 2025, 9:47 – 10:17 AM PT
  Moderators: Anat Loewenstein, MD, MHA & Daniel F. Martin, MD
• Panel: Designing Pivotal Trials Aligned with Evolving Regulatory Guidance
  Saturday, June 21, 2025, 12:45 – 1:05 PM PT
  Panelist: Peter K. Kaiser, MD, Chief Development Officer
• Panel: Shifting the Landscape: Can Innovation Truly Change the Paradigm?
  Saturday, June 21, 2025, 5:25 – 5:45 PM PT
  Moderator: Peter K. Kaiser, MD, Chief Development Officer

Learn more about OTX-TKI

Ophthalmology Times spoke with Dilsher S. Dhoot, MD, at the Retina World Congress meeting in Fort Lauderdale, Florida in May of 2025. During this interview, he shared insights on the HELIOS trial in which OTX-TKI was evaluated as a potential treatment for diabetic retinopathy and demonstrated promising results for a potential new treatment approach.

We also spoke with Justis P. Ehlers, MD, about a post hoc analysis which looked at the impact of OTX-TKI on macular fluid metrics in patients with NPDR without center-involved diabetic macular edema.

In early June 2025, Ocular Therapeutix has closed enrollment in its SOL-R registrational trial of its product candidate AXPAXLI (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD).

References:

1. Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025. Ocular Therapeutix. June 16, 2025. Accessed June 18, 2025. https://www.morningstar.com/news/globe-newswire/9468689/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025

2. Crago, SM. Q&A: Dilsher S. Dhoot, MD, on the HELIOS trial for diabetic retinopathy. May 10, 2025. Accessed June 18, 2025. https://www.ophthalmologytimes.com/view/q-a-dilsher-s-dhoot-md-on-the-helios-trial-for-diabetic-retinopathy

3. Ehlers, JP. Crago, SM. Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial. June 11, 2025. Accessed June 18, 2025. https://www.ophthalmologytimes.com/view/q-a-justis-p-ehlers-md-on-the-phase-1-helios-npdr-trial

4. Harp, MD. Ocular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMD. June 2, 2025. Accessed June 18, 2025. https://www.ophthalmologytimes.com/view/ocular-therapeutix-closes-enrollment-in-phase-3-sol-r-clinical-trial-for-wet-amd